cyrilzakka/clinical-trials huggingface dataset:
Vagal Nerve Stimulation in Irritable Bowel Syndrome

This randomized control trial aims to evaluate the effect of transcutaneous auricular vagal nerve stimulation in patients with irritable bowel syndrome. The intervention will be 8 weeks of treatment with a vagal nerve stimulator. The main objectives are:

* To evaluate the clinical response, defined as a decrease of at least 50 points on the IBS-SSS questionnaire, of the treatment.
* To ascertain whether the autonomic-vagal neurosignature, derived from pre-treatment registration of symptom profiles, autonomic responses and imaging of neuronal activity as a reaction to stress is able to predict therapeutic response to tVNS accurately.
* To evaluate the effect of treatment on quality of life
* To evaluate the effect of treatment on depression
* To evaluate the effect of treatment on anxiety Participants will be asked to wear a wearable (Fitbit) and fill out a daily questionnaire for one week. Thereafter, a functional brain MRI will be performed.

In the intervention group patients will receive transcutaneous nerve stimulation for 8-weeks at home. The comparison group will receive the same device but with a non-conducting electrode.

Patients fill out weekly questionnaires during the treatment period and at follow-up moments 3 and 6 months after finishing the treatment period.


Eligibility Criteria:
Inclusion Criteria:

* A diagnosis of IBS according to Rome IV criteria (3), as follows:
* Recurrent abdominal pain, on average, at least 1 day per week in the last 3 months, associated with 2 or more of the following criteria:
* Related to defecation.
* Associated with a change in stool frequency.
* Associated with a change in stool from (appearance).
* Criteria fulfilled for the last 3 months with symptom onset at least 6 months prior to diagnosis.
* Age between 18 and 75 years;
* Ability to understand and speak the Dutch language.
* Ability to understand how to utilize the ESM application.

Exclusion Criteria:

* A history of abdominal surgery, except for uncomplicated appendectomy, laparoscopic cholecystectomy and hysterectomy is present or otherwise based on the principal investigator's judgement.
* Presence of metallic prostheses, pacemakers, metal clips on blood vessels, metal parts in the eye, an intrauterine device (with the exception of the Mirena IUD), metal braces, facial tattoos and/or metal objects.
* History of major head trauma or head/brain surgery
* History of claustrophobia
* Pregnancy, lactation, intention to become pregnant during the study period
* Students and employees of Maastricht University are not precluded from participation, unless they have a direct personal, professional or hierarchical position with regards to any of the study team members or their department.
* If the subject has a cardiac arrhythmia, the attending physician will be consulted before participation.
Impact of the COVID-19 Pandemic in Gynecological Oncology

The current infection with the Coronavirus SARS-CoV-2 (COVID-19) is an exceptional health situation which requires an adaptation of our management practices in gynecological oncology. Data from the literature suggest that infection with Coronavirus is serious in subjects with cancer with a risk of severe form 5 times higher than that of the population without cancer and a risk of death multiplied by 8. In addition, the risk of infection would be 3 times greater in case of cancer. Faced with the COVID-19 epidemic, the investigator must organize themselves to ensure continuity in the treatment of patients with gynecological cancer but also adapt our practices in the management (CPR, teleconsultation, adaptation of treatment or even postponement of treatment). The objective of the High Council of Public Health is to be able to ensure adequate oncological care avoiding any potential loss of chance concerning the care of cancer: people affected must, despite the pandemic, have care allowing the same level of curability (localized cancers) or the same life expectancy (advanced cancers). This must be done by limiting as much as possible the impact on the organization of the service, the organization of patient follow-up and the psychological impact that these possible modifications could have. The hypotheses of our study are that the exceptional health situation linked to this pandemic leads to a change in the care of patients with gynecological cancer associated with a psychological impact and increased anxiety of patients during their care. Despite the extent of the pandemic, very little existing data makes it possible to define recommendations with a sufficient level of evidence.


Eligibility Criteria:
Inclusion Criteria:

* women over 18
* gynecological cancer (breast cancer, uterus, ovary, cervix, vagina or vulva cancer)
* therapeutic management planned during quarantine
* person having expressed his non-opposition

Inclusion Criteria of control group :

* women over 18
* gynecological cancer (breast, uterus, ovary, cervix, vagina or vulva cancer)
* therapeutic management planned on the end of the year 2019
* person having expressed his non-opposition

Exclusion Criteria:

* inability to understand the information given
* person deprived of liberty,
* person under guardianship.
Prehospital Tracheal Intubation Technique Using Initial Direct Laryngoscopy During Videolaryngoscopy

Tracheal intubation using videolaryngoscopy may be required in the prehospital setting, where airway management presents unique technical and logistical challenges. Intubation may be hard because novice providers performing videolaryngoscopy may only look at the screen and only obtain a two-dimensional representation of the patient's airways. By directly visualizing the airways, these providers may obtain a better 3D apprehension and an improved mental visualization of the patient's anatomy. We aim to compare the impact of a freely realized videolaryngoscopy sequence with a sequence consisting in direct visualization of the airway followed by videolaryngoscopy ("Direct Laryngoscopy-to-VideoLaryngoscopy sequence" or "DL-VL sequence") on time to intubation among novice providers.


Eligibility Criteria:
Inclusion Criteria:

* All resident physicians with 1 to 6 years of post-graduate experience working in the Emergency Department (ED) at Geneva University Hospitals (Hôpitaux Universitaires de Genève (HUG)) and penultimate year of medical school students (5th year) studying at University of Geneva Faculty of Medicine (UGFM).
* Performed less than 10 ETIs prior to participating in the study.

Exclusion Criteria:

* More than 6 years of post-graduate experience
* Performed more than 10 ETIs prior to participating in the study.
Deferoxamine In the Treatment of Aneurysmal Subarachnoid Hemorrhage (aSAH)

Aneurysmal subarachnoid hemorrhage (aSAH) has a high incidence of mortality and significant morbidity, with mortality exceeding 30% in the first two days.The initial injury is related to increasing intracranial pressure, cerebral edema, and neuronal injuries associated with the release of iron. Iron has been shown to increase the incidence of cerebral edema, ischemia, and formation of hydrocephalus. Deferoxamine mesylate (DFO), a hydrophilic chelator, creates a stable complex with free iron thus preventing the formation of iron related free radicals.

This trial will evaluate the safety and efficacy of clinical deferoxamine for the treatment of aSAH for patients that are admitted to the hospital at the University of Michigan or Peking University Health Science Center. Eligible participants will be enrolled and randomized to 1 of 2 doses of Deferoxamine or placebo (saline). Information regarding the patients will be collected and followed for up to 6 months post discharge.


Eligibility Criteria:
Inclusion Criteria:

* Aneurysmal SAH confirmed with vascular imaging
* Aneurysm treated with endovascular or microsurgical intervention
* Hunt-Hess ≤ 4
* Modified Fisher Grade I-IV
* Glasgow Coma Scale (GCS) ≥ 7 following External Ventricular Drain (EVD) placement if indicated
* First dose of drug can be administered within 24 hours of symptom onset
* Functional independence prior to SAH, Modified Rankin Scale (mRS) ≤ 1
* Informed consent obtained by patient or legal authorized representative (LAR)

Exclusion Criteria:

* Previous hypersensitivity to or treatment with deferoxamine
* Presence of giant aneurysm (\>25 mm in size)
* Known severe iron deficiency anemia, Hemoglobin (Hgb) g/dl ≤ 7 or transfusion dependent
* Irreversibly impaired brainstem function
* Abnormal renal function, Serum Creatinine\> 2 mg/dL
* Pre-existing severe disability, mRS ≥ 2
* Coagulopathy, including use of anti-platelet or anticoagulant drugs
* Known severe hearing loss
* Patients with significant respiratory disease such as chronic obstructive pulmonary disease, pulmonary fibrosis, or on home oxygen (O2)
* Taking iron supplements containing \> 325 mg of ferrous iron
* Pregnancy
* Life expectancy less than 90 days due to co-morbidities
* Concurrent participation in another research protocol for investigation of another experimental therapy, though observational studies are allowed
* Prior history of hepatic dysfunction
* Known cytopenia (platelets \< 50,000, Absolute neutrophil count \< 500)
Preoperative Alignment of Total Knee Replacement

The hypothesis of this study is that total knee alignment will be improved by preoperative planning from CT scans and the production of custom instruments compared to the use of standard instruments.

Patients will be randomized to have either customized knee instruments or standard generic instrumentation for primary total knee replacement. Postoperative CT scan will be used to determine alignment of each group.

Eligibility Criteria:
Inclusion Criteria:patients undergoing primary total knee replacement -

Exclusion Criteria:patients who have hardware involving the hip, knee or ankle

-
Increasing Caregiver and Patient Engagement Through PHR Use

Informal caregivers play an integral role in managing complex, chronic disease patients providing services equivalent to an estimated economic value of $470 billion. The inclusion of informal caregivers in the healthcare team can improve care coordination and make health care safer by reducing potential medical errors caused by miscommunication. the investigators reason that a properly designed PHR with a simplified user interface and easy access to relevant content can improve the management of chronic diseases and better integrate caregivers and patients into the healthcare team.

Informal caregivers (caregivers, often family or friends) play an integral role in managing patients with complex, chronic diseases. It is estimated that caregivers provide $470 billion of uncompensated care. Despite their impact, healthcare systems largely neglect caregivers. Long distance caregivers of older adults (who make up 15% of caregivers in America) are at a particular disadvantage. In the current healthcare system, health information technology (HIT) has not been optimized to support the needs of caregivers and patients. Providing HIT that supports enhanced communication between patients, caregivers, and clinicians can improve patient safety by increasing the accuracy of patient data and by reducing miscommunication(1).

There is limited knowledge concerning best practices to promote caregivers' and patients' activation and engagement, especially with HIT. Access to personal health information through the personal health record (PHR) has the potential to improve chronic health care management, and encourage patient engagement. Although caregivers and patients express a willingness to adopt PHRs, in practice, multiple barriers hinder PHR adoption. A properly designed PHR can help caregivers and patients manage their health and become partners in the healthcare team.

This study's overall objective is to identify caregivers and cardiovascular patients' communication and technology needs and to build and test an optimized PHR design that promotes active participation of patients and their caregivers in their health. The overall hypothesis is that an optimized PHR will expand the role of caregivers to improve the patient's health and improve the satisfaction of both patients and caregivers with their care. The investigators will employ an agile, user-centered design process involving caregivers and older cardiovascular patients.

Eligibility Criteria:
Inclusion Criteria:

* Eligible patients will be patients with heart disease, able read, write, and speak English, and at least 65 years of age.
* Eligible caregivers will be a primary caregiver of an eligible patient, able to read, write, and speak English, and at least 18 years of age.

Exclusion Criteria:

* Individuals under the age of 19 will not be considered for participation.
Effectiveness of Primary Care Physicians in Delivering Weight Control Counseling

This randomized clinical trial will determine the efficacy of physicians providing weight control advice to their overweight and obese patients in primary care practice.

Enrolled physicians are randomly assigned to receive brief training in either: 1) behavioral weight control intervention or 2) obesity education. Enrolled patients are asked to see their physician for 2 weight control consultations during the year to discuss their weight and physical activity. Regardless of the training the physician receives, the weight control advice is tailored to the individual patient. Patients include men and women between the ages of 21 - 70 years, with a Body-Mass Index of 27 or greater, and they have met medical and other study eligibility criteria in order to safely participate. As a participant in the trial, all patients are asked to attend an initial baseline assessment, and two follow-up assessments; 3 and 12 months after their first weight control consultation visit with their physician in order to evaluate any changes in their weight, waist circumference, physical activity, eating patterns, and mood. The findings of this important study will shed light upon the role physician advice may have in helping overweight and obese patients lose weight and become more physically active.

Eligibility Criteria:
Inclusion Criteria:

* Body-Mass Index greater than or equal to 27
* Able to walk without assistance
* No untreated hypothyroidism or Cushing Disease
* No unstable medical or psychiatric condition
* No signs or symptoms of cardiovascular disease
* No history of gallstones
* No terminal illness
* No other acute or chronic medical condition in which weight loss is contraindicated
* Medically cleared for physical activity

Exclusion Criteria:

* Pregnant, nursing or planning to become pregnant in the next year
* Had an in-patient hospital stay in the last 3 months
* Lost more than 10 lbs in the last 4 months
* Taking an OTC or prescribed medication for weight loss
* In treatment for an eating disorder
* In treatment for depression (if patient is on an anti-depressant and has not had a recent episode of depression in the past 3 months then he/she is eligible)
The Correlation Between the Metabolism and the Functional Status of Multiple Organs in the Early Stage of Diquat Poisoning

Diquat (DQ), as a conductive biocidal herbicide, is classified as medium according to Chinese pesticide toxicity classification standards. Since the sale and use of paraquat are stopped in 2016, incidents of diquat poisoning have begun to increase. Diquat is very toxic to the human body. Mistake of Diquat can cause damage to multiple organs throughout the body. It has a high fatality rate and no specific treatment.The treatment method has become a research hotspot of modern poisoning treatment.

The degree of organ dysfunction caused by DQ poisoning is mainly related to the patient's intake and the distribution of the poison in the human body.So far, the distribution concentration of DQ under the influence of the time gradient in the body and the influence of DQ on the human environment，metabolimics,，immune regulation activity and the comprehensive mechanism of action of various inflammatory factors have not been fully elucidated. Therefore, this research mainly focuses on analyzing the internal environment metabolism research in patients with DQ poisoning, and to conduct exploratory research on the severity of the impact on their organ functions


Eligibility Criteria:
Inclusion Criteria:

1.Time from poisoning to hospital admission: within 6 hours, 2 The age is greater than 18 years old, less than 65 years old 3 There is at least one target organ dysfunction 4 Previous physical fitness 5 No bad habits (drug use, alcohol addiction)

Exclusion Criteria:

1. Refuse to join this study
2. Missing/incomplete information
3. Pregnant women, vulnerable groups such as those who have no capacity for civil conduct and cannot determine the consent of their attorneys
4. Chronic organ dysfunction (chronic heart insufficiency, chronic respiratory insufficiency, chronic renal insufficiency, chronic Liver insufficiency)
5. Tumors, blood system diseases, various systemic immune diseases
6. Various infectious diseases (various hepatitis, tuberculosis, AIDS)
A Phase III Study of A01016 in Subjects With Symptomatic Vitreomacular Adhesion

The purpose of this study is to evaluate the superiority regarding vitreomacular adhesion (VMA) resolution of a single intravitreal injection of A01016 (Ocriplasmin) compared to sham-injection in subjects with symptomatic VMA.


Eligibility Criteria:
Inclusion Criteria:

* Symptomatic vitreomacular adhesion (VMA) which, in the opinion of the Investigator, is related to decreased visual function;
* Best corrected visual acuity (BCVA) of 20/25 or worse in the study eye;
* BCVA of 20/800 or better in the non-study eye;
* Provide written informed consent;
* Follow specified instructions during study period;
* Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

* Evidence of proliferative retinopathy, exudative age-related macular degeneration, or retinal vein occlusion in the study eye;
* Vitreous hemorrhage or other opacification;
* High myopia in the study eye;
* Ocular surgery, laser photocoagulation treatment, or intravitreal injection(s) in the study eye in the prior 3 months;
* Uncontrolled glaucoma in the study eye;
* History of retinal detachment in either eye;
* Active infection in either eye;
* Pregnant or of child-bearing potential and not utilizing acceptable form of contraception;
* Participation in another investigational drug study within 30 days prior to this study;
* Other protocol-defined exclusion criteria may apply.
Evaluation of the Relevance of Pharmacogenetics in the Prescription Off Antidepressants in a Military Population

The treatment of depression, anxiety disorders and post-traumatic stress disorder (PTSD) is a main public health problem due to the frequency of these pathologies and the very partial effectiveness of the existent therapies. These illnesses generally require the prescription of several successive lines of antidepressant treatments before the treatments actually become effective, leading to a several week delay during which the patient suffers from the symptoms of his/her pathology and is also likely to experience the side effects of the treatment.

Pharmacogenetics is an individualized prescribing modality that aims to predict the most favorable treatment for a given individual based on the study of genetic variants of cytochromes.

The main hypothesis of this research is that the use of pharmacogenetics in routine practice in a population of military personnel requiring a first prescription of an antidepressant is of interest to improve the tolerance and effectiveness of the treatment.


Eligibility Criteria:
Inclusion Criteria:

* Between 18 and 65 years-old;
* To benefit from a medical follow-up in the psychiatric department of an army training hospital;
* To present a pathology requiring an antidepressant treatment and whose prescription can wait 10 days;
* To have given written informed consent to participate in the study.

Exclusion Criteria:

* To be currently treated with an antidepressant or antidepressant stopped less than 15 days ago;
* To have one or more contraindication to the introduction of an antidepressant treatment;
* Pregnancy or breastfeeding;
* To require a measure of constraint.
Effectiveness of Therapeutic Alliance and Minimal Intervention for Chronic Low Back Pain

This study aims to evaluate the effectiveness of minimal intervention and therapeutic alliance in pain, specific and general disability, global perceived effect, empathy, credibility and expectation of improvement in patients with chronic non-specific low back pain

Low back pain remains a global public health problem. The classification of patients in low back pain subgroups aims to optimize the health system and provide the quantity and the type of proper technique for each patient. Several factors may influence physical therapy. The therapeutic alliance may be defined as harmony or social connection between the therapist and the patient and may influence the treatment effect. The aim of this study is to evaluate the effectiveness of the addition of the therapeutic alliance to a minimum intervention for the treatment of chronic non-specific low back pain with low risk of psychosocial factors.

Eligibility Criteria:
Inclusion Criteria

* Patients waiting for treatment in the waiting list of physical therapy clinics
* Diagnosis of chronic non-specific low back pain (over 12 weeks)
* More than 18 years
* Able to read and write the Portuguese language
* Low risk of psychosocial factors (less than 3 points in the STarT Back Screening Tool).

Exclusion criteria

* Spine surgery history
* Nerve root compromise
* Cognitive impairment related disorders
* Pregnants